TY - JOUR
TI - Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21
AU - Zhang, M.
AU - Wang, Z.
AU - Obazee, O.
AU - Jia, J.
AU - Childs, E.J.
AU - Hoskins, J.
AU - Figlioli, G.
AU - Mocci, E.
AU - Collins, I.
AU - Chung, C.C.
AU - Hautman, C.
AU - Arslan, A.A.
AU - Beane-Freeman, L.
AU - Bracci, P.M.
AU - Buring, J.
AU - Duell, E.J.
AU - Gallinger, S.
AU - Giles, G.G.
AU - Goodman, G.E.
AU - Goodman, P.J.
AU - Kamineni, A.
AU - Kolonel, L.N.
AU - Kulke, M.H.
AU - Malats, N.
AU - Olson, S.H.
AU - Sesso, H.D.
AU - Visvanathan, K.
AU - White, E.
AU - Zheng, W.
AU - Abnet, C.C.
AU - Albanes, D.
AU - Andreotti, G.
AU - Brais, L.
AU - Bas Bueno-de-Mesquita, H.
AU - Basso, D.
AU - Berndt, S.I.
AU - Boutron-Ruault, M.-C.
AU - Bijlsma, M.F.
AU - Brenner, H.
AU - Burdette, L.
AU - Campa, D.
AU - Caporaso, N.E.
AU - Capurso, G.
AU - Cavestro, G.M.
AU - Cotterchio, M.
AU - Costello, E.
AU - Elena, J.
AU - Boggi, U.
AU - Michael Gaziano, J.
AU - Gazouli, M.
AU - Giovannucci, E.L.
AU - Goggins, M.
AU - Gross, M.
AU - Haiman, C.A.
AU - Hassan, M.
AU - Helzlsouer, K.J.
AU - Hu, N.
AU - Hunter, D.J.
AU - Iskierka-Jazdzewska, E.
AU - Jenab, M.
AU - Kaaks, R.
AU - Key, T.J.
AU - Khaw, K.-T.
AU - Klein, E.A.
AU - Kogevinas, M.
AU - Krogh, V.
AU - Kupcinskas, J.
AU - Kurtz, R.C.
AU - Landi, M.T.
AU - Landi, S.
AU - Marchand, L.L.
AU - Mambrini, A.
AU - Mannisto, S.
AU - Milne, R.L.
AU - Neale, R.E.
AU - Oberg, A.L.
AU - Panico, S.
AU - Patel, A.V.
AU - Peeters, P.H.M.
AU - Peters, U.
AU - Pezzilli, R.
AU - Porta, M.
AU - Purdue, M.
AU - Ramón Quiros, J.
AU - Riboli, E.
AU - Rothman, N.
AU - Scarpa, A.
AU - Scelo, G.
AU - Shu, X.-O.
AU - Silverman, D.T.
AU - Soucek, P.
AU - Strobel, O.
AU - Sund, M.
AU - Malecka-Panas, E.
AU - Taylor, P.R.
AU - Tavano, F.
AU - Travis, R.C.
AU - Thornquist, M.
AU - Tjønneland, A.
AU - Tobias, G.S.
AU - Trichopoulos, D.
AU - Vashist, Y.
AU - Vodicka, P.
AU - Wactawski-Wende, J.
AU - Wentzensen, N.
AU - Yu, H.
AU - Yu, K.
AU - Zeleniuch-Jacquotte, A.
AU - Kooperberg, C.
AU - Risch, H.A.
AU - Jacobs, E.J.
AU - Li, D.
AU - Fuchs, C.
AU - Hoover, R.
AU - Hartge, P.
AU - Chanock, S.J.
AU - Petersen, G.M.
AU - Stolzenberg-Solomon, R.S.
AU - Wolpin, B.M.
AU - Kraft, P.
AU - Klein, A.P.
AU - Canzian, F.
AU - Amundadottir, L.T.
JO - OncoTargets and therapy
PY - 2016
VL - 7
TODO - 41
SP - 66328-66343
PB - Impact Journals, LLC
SN - null
TODO - 10.18632/oncotarget.11041
TODO - liver receptor homolog 1;  Myc protein;  telomerase reverse transcriptase, Article;  bioinformatics;  cancer risk;  cancer susceptibility;  case control study;  chromosome;  chromosomes 1q32.1;  chromosomes 5p15.33;  chromosomes 8q24.21;  CLPTM1L gene;  controlled study;  down regulation;  gene expression;  gene frequency;  gene locus;  genetic association;  genetic risk;  genetic variability;  genome analysis;  histopathology;  human;  human tissue;  major clinical study;  NR5A2 gene;  oncogene;  oncogene myc;  pancreas cancer;  signal transduction;  single nucleotide polymorphism;  TERT gene;  chromosome 1;  chromosome 5;  chromosome 8;  genetic predisposition;  genetics;  genome-wide association study;  genotype;  information processing;  pancreas tumor;  procedures, Chromosomes, Human, Pair 1;  Chromosomes, Human, Pair 5;  Chromosomes, Human, Pair 8;  Datasets as Topic;  Genetic Predisposition to Disease;  Genome-Wide Association Study;  Genotype;  Humans;  Pancreatic Neoplasms;  Polymorphism, Single Nucleotide
TODO - Genome-wide association studies (GWAS) have identified common pancreatic cancer susceptibility variants at 13 chromosomal loci in individuals of European descent. To identify new susceptibility variants, we performed imputation based on 1000 Genomes (1000G) Project data and association analysis using 5,107 case and 8,845 control subjects from 27 cohort and case-control studies that participated in the PanScan I-III GWAS. This analysis, in combination with a two-staged replication in an additional 6,076 case and 7,555 control subjects from the PANcreatic Disease ReseArch (PANDoRA) and Pancreatic Cancer Case-Control (PanC4) Consortia uncovered 3 new pancreatic cancer risk signals marked by single nucleotide polymorphisms (SNPs) rs2816938 at chromosome 1q32.1 (per allele odds ratio (OR) = 1.20, P = 4.88x10-15), rs10094872 at 8q24.21 (OR = 1.15, P = 3.22x10-9) and rs35226131 at 5p15.33 (OR = 0.71, P = 1.70x10-8). These SNPs represent independent risk variants at previously identified pancreatic cancer risk loci on chr1q32.1 (NR5A2), chr8q24.21 (MYC) and chr5p15.33 (CLPTM1L-TERT) as per analyses conditioned on previously reported susceptibility variants. We assessed expression of candidate genes at the three risk loci in histologically normal (n = 10) and tumor (n = 8) derived pancreatic tissue samples and observed a marked reduction of NR5A2 expression (chr1q32.1) in the tumors (fold change -7.6, P = 5.7x10-8). This finding was validated in a second set of paired (n = 20) histologically normal and tumor derived pancreatic tissue samples (average fold change for three NR5A2 isoforms -31.3 to -95.7, P = 7.5x10-4-2.0x10-3). Our study has identified new susceptibility variants independently conferring pancreatic cancer risk that merit functional follow-up to identify target genes and explain the underlying biology.
ER -